COV-BT Ire study: safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with brain tumors

BACKGROUND: The BNT162b2 vaccine conferred 95% protection against COVID-19 in people aged 16 years or older. OBJECTIVE: The aim of this observational study was to evaluate safety and efficacy of vaccine in patients affected by primary brain tumor (PBT). METHODS: We proposed COVID-19 vaccine to all p...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanzilli, Antonio, Pace, Andrea, Ciliberto, Gennaro, La Malfa, Antonia Marina, Buonomo, Valentina, Benincasa, Dario, Biscu, Annamaria, Galiè, Edvina, Villani, Veronica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Covid-19
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8994182/
https://www.ncbi.nlm.nih.gov/pubmed/35397014
http://dx.doi.org/10.1007/s10072-022-06054-3
_version_ 1784684057004605440
author Tanzilli, Antonio
Pace, Andrea
Ciliberto, Gennaro
La Malfa, Antonia Marina
Buonomo, Valentina
Benincasa, Dario
Biscu, Annamaria
Galiè, Edvina
Villani, Veronica
author_facet Tanzilli, Antonio
Pace, Andrea
Ciliberto, Gennaro
La Malfa, Antonia Marina
Buonomo, Valentina
Benincasa, Dario
Biscu, Annamaria
Galiè, Edvina
Villani, Veronica
author_sort Tanzilli, Antonio
collection PubMed
description BACKGROUND: The BNT162b2 vaccine conferred 95% protection against COVID-19 in people aged 16 years or older. OBJECTIVE: The aim of this observational study was to evaluate safety and efficacy of vaccine in patients affected by primary brain tumor (PBT). METHODS: We proposed COVID-19 vaccine to all patients affected by PBT followed by Neuroncology Unit of National Cancer Institute Regina Elena. RESULTS: 102 patients received the first dose, 100 the second, and 73 patients received the booster dose. After first dose, we observed one patient with fever and severe fatigue, while after the second one, we recorded adverse events in ten patients. No correlation was observed between adverse events and comorbidities. CONCLUSIONS: The COVID-19 vaccine is safe and well tolerated in PBT patients.
format Online
Article
Text
id pubmed-8994182
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-89941822022-04-11 COV-BT Ire study: safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with brain tumors Tanzilli, Antonio Pace, Andrea Ciliberto, Gennaro La Malfa, Antonia Marina Buonomo, Valentina Benincasa, Dario Biscu, Annamaria Galiè, Edvina Villani, Veronica Neurol Sci Covid-19 BACKGROUND: The BNT162b2 vaccine conferred 95% protection against COVID-19 in people aged 16 years or older. OBJECTIVE: The aim of this observational study was to evaluate safety and efficacy of vaccine in patients affected by primary brain tumor (PBT). METHODS: We proposed COVID-19 vaccine to all patients affected by PBT followed by Neuroncology Unit of National Cancer Institute Regina Elena. RESULTS: 102 patients received the first dose, 100 the second, and 73 patients received the booster dose. After first dose, we observed one patient with fever and severe fatigue, while after the second one, we recorded adverse events in ten patients. No correlation was observed between adverse events and comorbidities. CONCLUSIONS: The COVID-19 vaccine is safe and well tolerated in PBT patients. Springer International Publishing 2022-04-09 2022 /pmc/articles/PMC8994182/ /pubmed/35397014 http://dx.doi.org/10.1007/s10072-022-06054-3 Text en © Fondazione Società Italiana di Neurologia 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Covid-19
Tanzilli, Antonio
Pace, Andrea
Ciliberto, Gennaro
La Malfa, Antonia Marina
Buonomo, Valentina
Benincasa, Dario
Biscu, Annamaria
Galiè, Edvina
Villani, Veronica
COV-BT Ire study: safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with brain tumors
title COV-BT Ire study: safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with brain tumors
title_full COV-BT Ire study: safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with brain tumors
title_fullStr COV-BT Ire study: safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with brain tumors
title_full_unstemmed COV-BT Ire study: safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with brain tumors
title_short COV-BT Ire study: safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with brain tumors
title_sort cov-bt ire study: safety and efficacy of the bnt162b2 mrna covid-19 vaccine in patients with brain tumors
topic Covid-19
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8994182/
https://www.ncbi.nlm.nih.gov/pubmed/35397014
http://dx.doi.org/10.1007/s10072-022-06054-3
work_keys_str_mv AT tanzilliantonio covbtirestudysafetyandefficacyofthebnt162b2mrnacovid19vaccineinpatientswithbraintumors
AT paceandrea covbtirestudysafetyandefficacyofthebnt162b2mrnacovid19vaccineinpatientswithbraintumors
AT cilibertogennaro covbtirestudysafetyandefficacyofthebnt162b2mrnacovid19vaccineinpatientswithbraintumors
AT lamalfaantoniamarina covbtirestudysafetyandefficacyofthebnt162b2mrnacovid19vaccineinpatientswithbraintumors
AT buonomovalentina covbtirestudysafetyandefficacyofthebnt162b2mrnacovid19vaccineinpatientswithbraintumors
AT benincasadario covbtirestudysafetyandefficacyofthebnt162b2mrnacovid19vaccineinpatientswithbraintumors
AT biscuannamaria covbtirestudysafetyandefficacyofthebnt162b2mrnacovid19vaccineinpatientswithbraintumors
AT galieedvina covbtirestudysafetyandefficacyofthebnt162b2mrnacovid19vaccineinpatientswithbraintumors
AT villaniveronica covbtirestudysafetyandefficacyofthebnt162b2mrnacovid19vaccineinpatientswithbraintumors

Ejemplares similares